Editas Medicine EDIT
NASDAQ EDIT
$3.15 +0.08 (+2.44%)
As of: Sep 4, 2026 · 3:12 PM EDT

Editas Medicine (EDIT) Non Operating Interest Expenses (2025)

Analysis

Editas Medicine (EDIT) Non Operating Interest Expenses (2025) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.58 Bn 130.73 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.33 Bn 77.33 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.43 Bn 58.24 Bn 1.37 Bn -1.00 Mn
4 Moderna 57.84 Bn 52.70 Bn 52.00 Mn -
5 Revolution Medicines 44.01 Bn 44.01 Bn - 23.78 Mn
6 BeOne Medicines 39.93 Bn 34.83 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.47 Bn 32.16 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.39 Bn 27.56 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 Editas Medicine 284.24 Mn 137.59 Mn - -
Historic Data

Historic Data

Download Data
DateValue
Sep 30, 2025 2.40 Mn
Jun 30, 2025 2.02 Mn
Mar 31, 2025 2.22 Mn